Vitespen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Vitespen
Accession Number
DB06400
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Description
Not Available
Synonyms
  • Endoplasmin (human tumor rejection antigen 1)
  • Heat shock protein-peptide complex-96 vaccine
  • Vitespen
External IDs
HSPPC 96 / HSPPC-96
Categories
UNII
H3598Y1TLJ
CAS number
492448-75-6

Pharmacology

Indication

Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.

Pharmacodynamics
Not Available
Mechanism of action

HSPPC-96 is a protein peptide complex consisting of a 96 kDa heat shock protein (Hsp), gp96, and an array of gp96-associated cellular peptides. Immunisation with HSPPC-96 induces T-cell specific immunity against these peptides; gp96 is not immunogenic per se. The non-covalent binding of gp96 to peptides is neither selective nor restricted to cell types. Thus, the collection of gp96-associated peptides represents the antigenic peptide pool of a cell; this is the basis of the peptide-specific immunogenicity elicited by HSPPC-96.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Vitespen can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Vitespen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Vitespen can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Vitespen can be decreased when used in combination with Abetimus.
ActeosideThe therapeutic efficacy of Vitespen can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Vitespen can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Vitespen can be decreased when used in combination with Afelimomab.
AlclometasoneThe therapeutic efficacy of Vitespen can be decreased when used in combination with Alclometasone.
AldesleukinThe therapeutic efficacy of Vitespen can be decreased when used in combination with Aldesleukin.
AldosteroneThe therapeutic efficacy of Vitespen can be decreased when used in combination with Aldosterone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Minev BR: Technology evaluation: HSPPC-96, antigenics. Curr Opin Mol Ther. 2003 Dec;5(6):680-7. [PubMed:14755896]
  2. Caudill MM, Li Z: HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther. 2001 May;1(3):539-47. [PubMed:11727524]
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentAnaplastic Ependymoma / Astrocytoma, Grade III / Clear Cell Ependymoma / Ependymomas / Glioblastoma Multiforme (GBM)1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2WithdrawnTreatmentMelanoma1
2Active Not RecruitingTreatmentGliosarcoma / Recurrent Adult Brain Tumor / Recurrent Glioblastoma1
2CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Pulmonary Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentFollicular Lymphoma (FL) / Small Lymphocytic Lymphoma1
2CompletedTreatmentSarcomas1
2Not Yet RecruitingTreatmentGlioma of Brain1
2RecruitingTreatmentGlioblastomas1
2TerminatedTreatmentRenal Cell Adenocarcinoma2
3CompletedTreatmentMalignant Melanoma1
3CompletedTreatmentRenal Cell Adenocarcinoma1
3TerminatedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:29 / Updated on December 02, 2019 07:22